Drug Targets – Products

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

CatSci Ltd are thrilled to announce that they have won a Welsh Government SMART Capital Equipment Fund grant to enhance their oligonucleotides capability and offer more and better R&D and manufacturing solutions to customers.

Cresset, announces a collaboration with Enamine to develop innovative new solutions for the early drug discovery process.

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech
research.

Download this compendium to learn more about developments in high-throughput screening, target-based drug discovery and fragment-based drug discovery.

Engaging in research is like participating in a high-stakes poker match. The potential reward? The discovery of the next blockbuster drug. The gamble? Risking billions on a molecule that doesn't pay off. In this game, the winning hand lies in the tools that can identify the most promising leads.

This app note highlights how reliable kinetics and affinity for high-affinity interactions can be obtained from significantly less data than is commonly used.

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.

Accurate kinetics and affinity data is essential for predicting the efficacy of novel therapeutics and for making quick decisions about weak candidates. However, analysis methods that require labelling can cause steric interference and influence data outcomes.

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.